Risk Factors for Symptomatic Gallstone Disease and Gallstone Formation After Bariatric Surgery.

Sylke Haal, Maimoena S S Guman, Sjoerd Bruin, Ruben Schouten, Ruben N van Veen, Paul Fockens, Marcel G W Dijkgraaf, Barbara A Hutten, Victor E A Gerdes, Rogier P Voermans

Journal: Obesity surgery 2022;32(4):1270-1278

PMID: 35143012

Abstract

PURPOSE

Patients who undergo bariatric surgery are at risk for developing cholesterol gallstones. We aimed to identify risk factors that are associated with symptomatic gallstone disease and gallstone formation after bariatric surgery.

MATERIALS AND METHODS

We included participants of the UPGRADE trial, a multicenter randomized placebo-controlled trial on the prevention of symptomatic gallstone disease with ursodeoxycholic acid (UDCA) after bariatric surgery. The association between patient characteristics and symptomatic gallstone disease, and gallstone formation was evaluated using logistic regression analysis.

RESULTS

Of 959 patients, 78 (8%) developed symptomatic gallstone disease within 24 months. Risk factors were the presence of a pain syndrome (OR 2.07; 95% CI 1.03 to 4.17) and asymptomatic gallstones before surgery (OR 3.15; 95% CI 1.87 to 5.33). Advanced age (OR 0.95; 95% CI 0.93 to 0.97) was protective, and UDCA prophylaxis did not reach statistical significance (OR 0.64; 95% CI 0.39 to 1.03). No risk factors were identified for gallstone formation, whereas advanced age (OR 0.98; 95% CI 0.96 to 1.00), statin use (OR 0.42; 95% CI 0.20 to 0.90), and UDCA prophylaxis (OR 0.47; 95% CI 0.30 to 0.73) all reduced the risk.

CONCLUSION

Young patients with a preoperative pain syndrome and/or asymptomatic gallstones before bariatric surgery are at increased risk for symptomatic gallstone disease after surgery. Whether statins, either alone or in combination with UDCA prophylaxis, can further reduce the burden of gallstones after bariatric surgery should be investigated prospectively.

© 2022. The Author(s).

Address: Department of Internal Medicine, Spaarne Gasthuis, 2134 TM, Hoofddorp, the Netherlands. [email protected].; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, 1105 AZ, Amsterdam, the Netherlands. [email protected].; Department of Internal Medicine, Spaarne Gasthuis, 2134 TM, Hoofddorp, the Netherlands.; Department of Internal and Vascular Medicine, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, 1105 AZ, Amsterdam, the Netherlands.; Department of Surgery, Spaarne Gasthuis, 2134 TM, Hoofddorp, the Netherlands.; Department of Surgery, Flevohospital, 1315 RA, Almere, the Netherlands.; Department of Surgery, OLVG, 1061 AE, Amsterdam, the Netherlands.; Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, 1105 AZ, Amsterdam, the Netherlands.; Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, 1105 AZ, Amsterdam, the Netherlands.; Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, 1105 AZ, Amsterdam, the Netherlands.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.